Patents Assigned to Immunex
  • Patent number: 6867013
    Abstract: The invention is directed to purified and isolated human polypeptides having kinase function, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in phosphorylation reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, the use of such polypeptides in screening assays, and kits comprising these reagents.
    Type: Grant
    Filed: December 18, 2001
    Date of Patent: March 15, 2005
    Assignee: Immunex Corporation
    Inventors: G. Duke Virca, Timothy A. Bird, Dirk M. Anderson, John S. Marken
  • Patent number: 6852486
    Abstract: A poxvirus protein designated A41L binds to leukocyte common-antigen-related protein (LAR). A41L is a secreted protein that can be purified from the culture supernatant of cells infected with certain poxviruses, or produced using recombinant DNA techniques. A41L polypeptides and LAR polypeptides, and nucleic acids encoding them, are provided herein. Also provided are methods of using such polypeptides and nucleic acids.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: February 8, 2005
    Assignee: Immunex Corp.
    Inventors: Craig A. Smith, Raymond G. Goodwin
  • Publication number: 20050013814
    Abstract: A method of treating a mammal afflicted with rheumatoid arthritis comprising administering a soluble form of IL-17 receptor is disclosed.
    Type: Application
    Filed: August 13, 2004
    Publication date: January 20, 2005
    Applicant: Immunex Corporation
    Inventor: Kendall Mohler
  • Patent number: 6842704
    Abstract: A tumor necrosis factor-? converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Grant
    Filed: February 4, 1999
    Date of Patent: January 11, 2005
    Assignees: Immunex Corporation, Max-Planck-Institute for Biochemistry, Wyeth
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Patent number: 6838262
    Abstract: Isolated ligands, DNAs encoding such ligands, and pharmaceutical compositions made therefrom, are disclosed. The isolated ligands can be used to regulate an immune response. The ligands are also useful in screening for inhibitors thereof.
    Type: Grant
    Filed: October 13, 2000
    Date of Patent: January 4, 2005
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, Laurent J. Galibert
  • Patent number: 6838290
    Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, the use of such polypeptides in cellular and immune reactions, the use of such polypeptides in screening for agonists or antagonists of IL-1 epsilon activity, and kits comprising such polypeptides.
    Type: Grant
    Filed: October 2, 2001
    Date of Patent: January 4, 2005
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Dirk E. Smith
  • Publication number: 20040265983
    Abstract: A tumor necrosis factor-&agr; converting enzyme (TACE) is produced, purified, and crystallized. The three-dimensional coordinates of the crystal are obtained by X-ray diffraction. The coordinates can be recorded on a computer readable medium, or are part of a video memory, where they can be used as part of a system for studying for studying TACE. The coordinates are also used in designing, screening, and developing compounds that associate with TACE.
    Type: Application
    Filed: February 24, 2004
    Publication date: December 30, 2004
    Applicants: IMMUNEX CORPORATION; MAX-PLANCK-INSTITUTE FOR BIOCHEMISTRY, WYETH
    Inventors: Roy A. Black, Raymond James Paxton, Wolfram Bode, Klaus Maskos, Carlos Fernandez-Catalan, James Ming Chen, Jeremy Ian Levin
  • Publication number: 20040253587
    Abstract: Antagonists of mammalian interleukin-15 (“IL-15”) are disclosed and include muteins of IL-15 and modified IL-15 molecules that are each capable of binding to the IL-15R&agr;-subunit and that are incapable of transducing a signal through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Also included are monoclonal antibodies against IL-15 that prevent IL-15 from effecting signal transduction through either the &bgr;- or &ggr;-subunits of the IL-15 receptor complex. Methods of treating various disease states are disclosed, including treating allograft rejection and graft-versus-host disease.
    Type: Application
    Filed: November 6, 2002
    Publication date: December 16, 2004
    Applicant: Immunex Corporation
    Inventors: Kenneth H. Grabstein, Dean K. Pettit, Raymond J. Paxton
  • Publication number: 20040253674
    Abstract: A new family of immunoreceptor molecules of the immunoglobulin superfamily, (LIR) polypeptides is described. Disclosed are sequences encoding LIR family members and their deduced amino acid sequences, polypeptides encoded by DNA that hybridize to oligonucleotide probes having defined sequences, processes for producing polypeptides of the LIR family, and antagonistic antibodies to LIR family members. LIR family members can be used to treat autoimmune diseases and disease states associated with suppressed immune function.
    Type: Application
    Filed: December 22, 2003
    Publication date: December 16, 2004
    Applicant: Immunex Corporation
    Inventor: David J. Cosman
  • Publication number: 20040253610
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Application
    Filed: January 8, 2004
    Publication date: December 16, 2004
    Applicant: Immunex Corporation
    Inventor: Steven R. Wiley
  • Publication number: 20040253682
    Abstract: 2F1 polypeptides are provided, along with DNA sequences, expression vectors and transformed host cells useful in producing the polypeptides. Soluble 2F1 polypeptides find use in inhibiting prostaglandin synthesis and treating inflammation.
    Type: Application
    Filed: May 28, 2004
    Publication date: December 16, 2004
    Applicant: Immunex Corporation
    Inventors: Patricia Parnet, John E. Sims
  • Publication number: 20040248187
    Abstract: The invention is directed to novel, purified and isolated IL-1 zeta and Xrec2 polypeptides and fragments thereof, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: July 9, 2004
    Publication date: December 9, 2004
    Applicant: Immunex Corporation
    Inventors: John E. Sims, Dirk E. Smith, Teresa L. Born
  • Publication number: 20040248254
    Abstract: The invention is directed to purified and isolated novel ACPL polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: December 15, 2003
    Publication date: December 9, 2004
    Applicant: Immunex Corporation
    Inventors: John E. Sims, Teresa L. Born
  • Publication number: 20040241758
    Abstract: There is disclosed a polypeptide (CD30-L) and DNA sequences, vectors and transformed host cells useful in providing CD30-L polypeptides. The CD30-L polypeptide binds to the receptor known as CD30, which is expressed on a number of cell types, among which are Hodgkin's Disease tumor cells, large cell anaplastic lymphoma cells, adult T-cell leukemia (T-ALL) cells, and a number of other malignant cell types. CD30-L polypeptides find use as carriers for delivering diagnostic and cytotoxic agents to cells expressing the CD30 receptor.
    Type: Application
    Filed: October 2, 2003
    Publication date: December 2, 2004
    Applicant: IMMUNEX CORPORATION
    Inventors: Raymond G. Goodwin, Craig A. Smith, Richard J. Armitage, Hans-Juergen Gruss
  • Patent number: 6824773
    Abstract: The present invention provides the TWEAK receptor and methods for identifying and using agonists and antagonists of the TWEAK receptor. In particular, the invention provides methods of screening for agonists and antagonists and for treating diseases or conditions mediated by angiogenesis, such as solid tumors and vascular deficiencies of cardiac or peripheral tissue.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: November 30, 2004
    Assignee: Immunex Corporation
    Inventor: Steven R. Wiley
  • Publication number: 20040220103
    Abstract: The invention pertains to methods and compositions for treating medical disorders characterized by elevated levels or abnormal expression of TNF&agr; by administering a TNF&agr; antagonist, such as recombinant TNFR:Fc.
    Type: Application
    Filed: May 25, 2004
    Publication date: November 4, 2004
    Applicant: Immunex Corporation
    Inventors: Barbara K. Finck, Larry O'Neal, John D. Pluenneke, Timothy Connor
  • Publication number: 20040210038
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: May 10, 2004
    Publication date: October 21, 2004
    Applicant: Immunex Corp.
    Inventors: John E. Sims, Blair R. Renshaw
  • Publication number: 20040203116
    Abstract: The invention is directed to novel, purified and isolated IL-1 eta polypeptides and fragments thereof, the polynucleotides encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, peptides derived from these polypeptides, and uses thereof.
    Type: Application
    Filed: May 10, 2004
    Publication date: October 14, 2004
    Applicant: Immunex Corp.
    Inventors: John E. Sims, Blair R. Renshaw
  • Publication number: 20040204568
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Application
    Filed: July 17, 2003
    Publication date: October 14, 2004
    Applicant: IMMUNEX CORPORATION
    Inventors: Peter Robert Baum, William Christian Fanslow
  • Patent number: 6794173
    Abstract: Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibitors or agonists thereof.
    Type: Grant
    Filed: June 20, 2002
    Date of Patent: September 21, 2004
    Assignee: Immunex Corporation
    Inventors: Dirk M. Anderson, G. Duke Virca